Marinus Pharmaceuticals Inc (MRNS)

NASDAQ
Currency in USD
0.550
0.000(0.00%)
Closed
Day's Range
0.5490.550
52 wk Range
0.2209.690
Key Statistics
Edit
Prev. Close
0.55
Open
0.549
Day's Range
0.549-0.55
52 wk Range
0.22-9.69
Volume
1.1M
Average Vol. (3m)
1.84M
1-Year Change
-93.84%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
Show more

Marinus Pharmaceuticals Inc Company Profile

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders, such as status epilepticus, CDKL5 deficiency disorder, and tuberous sclerosis complex. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company’s ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania. As of February 7, 2025, Marinus Pharmaceuticals, Inc. operates as a subsidiary of Immedica Pharma AB.

Employees
166

Marinus Pharmaceuticals Inc SWOT Analysis


Analyst Outlook
Discover varied analyst perspectives, with price targets ranging from $1 to $10, reflecting the company's high-risk, high-reward profile
Market Expansion
Learn how success in TSC could expand Marinus' addressable market sixfold, potentially transforming its industry position
Financial Tightrope
Delve into Marinus' financial strategy, balancing a $113.3M cash position against significant debt and negative EBITDA
Pipeline Promise
Explore Marinus Pharmaceuticals' potential breakthrough in tuberous sclerosis complex treatment, with top-line results expected in Q4 2024
Read full SWOT analysis

Marinus Pharmaceuticals Inc Earnings Call Summary for Q2/2024

  • Q2 net product revenues of $8M; 2024 guidance of $33-35M
  • ZTALMY launch for TSC planned for H2 2025; profitability expected 12-18 months post-launch
  • Cash runway extended to Q2 2025; cost reduction plans implemented
  • Successful patent litigation for IV ganaxolone; FDA meeting planned to discuss endpoints
  • Global expansion: ZTALMY launch in China early 2025; agreements in Europe, MENA, Russia
Last Updated: 08/13/2024, 06:58 PM
Read Full Transcript

Earnings

Latest Release
Mar 11, 2025
EPS / Forecast
-- / -0.3097
Revenue / Forecast
-- / 11.85M
EPS Revisions
Last 90 days
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.